not getting the job done, not moving fast enough, pretty much like most small biotech that over promise and under deliver, but even slower and worse in the case of ARNA and BIll S. The bigger questions are 1) do they have something of value 2) when will we know 3) will Munshi create value, or will he be another Jack Leif, do-nothing, focused on his personal wealth, or just not able to deliver...
looks like ACHN pattern is destined to repeat, at least the down 1 part. Looks like a good spot to buy/add for the potential ride to $11 IMO.
Short interest went down 1MM. It's a down market day, data is phase 1 in healthy volunteers. Maybe a little pullback to $9ish and then up 2 again to $11. I like this pattern.
interesting comment, how does one get out one's mind and if I did get out, where would I go? Not into your mind I hope.
Anyway, it's not a prediction it's a what if positive comment. I say each one is worth $20, either + Hep C or + FD. FD has the potential to be a franchise for many indications and is the stuff that could make an ALXN, CELG, or GILD over time and if it works. I would not be short this stock. IMO of course.
they can make their own similar products. UA is a better brand, that would be a stupid purchase.
It's very early stage. When we get great Phase II data, then we will really have something worth $20+ maybe by 3Q or 4Q 2017 and that's discounting HepC. Add another $10-20 if those results are +.
for coughing. Obesity, inflammation, opiod abuse, PAH...coughing??? 500MM vs. $1.25 BB. I report, you decide.
Does someone know something? Leaks are common in biotech. Large short position could add fuel to any fire. Just once I would like to participate long on a huge short squeeze.
agree, first they over-paid, which was good for ARNA, then they under-delivered, which was bad for ARNA/shareholders. Partner selection is KEY. When going through the process, maybe an acquirer will emerge, but probably not until 334 results. I hope they don't make acquiring too complex with too many partner deals, to much complexity. Sum of the parts should be worth far more then $2. ASAP is best for me, I would like to move on.
every biotech says that and most still get acquired. Hoping for an acquisition, small biotech co's usually mess up something in the filing or FDA approval process the first time, or in the launch.
before the last run to $14 I had a dream about a bean stalk growing strong and high. Last night I had a dream about ARNA having an offer to be acquired. The bean stalk went high, but withered quickly, I guess it was like the seed scattered on the rocks. An acquisition is like the seeds planted in good soil...a little Bible talk for your Thursday morning.
OK, I'll bite. What's happening on Wednesday? Why sell any this low and before the technical traders come in and drive this to $2.5 maybe tomorrow?
I'll agree with $4-5 and maybe $8 if we sign a great partner. Most of the clinical news is planned for next year no?